Pfizer Stock News

WASHINGTON D.C.: The U.S. Food and Drug Administration (FDA) is expected to approve, within days, Pfizer''s and Merck''s groundbreaking pills to treat COVID-19, sources told Bloomberg News. Writing in the Guardian, Eric Topol, director of the Scripps Research Translational Institute, said the approval of Pfizer''s Paxlovid and Merck''s Molnupiravir would come at a time "when we absolutely need it," amidst the surge

Barclays set a $54.00 price objective on Pfizer (NYSE:PFE) in a research note released on Thursday, Borsen Zeitung reports. PFE has been the topic of a number of other reports. Berenberg Bank reaffirmed a hold rating and set a $54.00 price objective on shares of Pfizer in a report on Tuesday, December 14th. SVB Leerink []

Washington, Dec 24 (IANS) While the US Food and Drug Administration (FDA) has approved Pfizer antiviral pill to treat Covid-19, the White House has warned that the drug will not be available in the markets before six-eight months. The US FDA on Wednesday issued an emergency use authorisation (EUA) for the Pfizers Paxlovid pill to [] The post Pfizers Covid pill will take about 6-8 months to come to US markets appeared first on Buziness Bytes .

(RTTNews) - French stocks held steady in a holiday-shortened session on Friday after data indicated that both Merck''s and Pfizer''s Covid-19 antiviral pills were effective against the Omicron variant. Investor sentiment remained supported amid optimism that the Omicron variant might be highly infections, but less likely to lead to hospitalization.

South Africa will start its COVID-19 booster vaccination campaign on Friday after previously approving booster shots developed by Johnson & Johnson as well as Pfizer and BioNTech. "From Dec

(RTTNews) - Asian stocks ended broadly higher on Friday after data indicated that both Merck''s and Pfizer''s Covid-19 antiviral pills were effective against the Omicron variant. Investor sentiment was buoyed by optimism that the Omicron variant might be highly infections, but less likely to lead to hospitalization. Another batch of upbeat U.S.

Both J&J and Pfizer COVID-19 shots have been authorised as boosters by the South African health regulatory department, but the move opens up boosters to the general public for the first time.

Food and Drug Administration (FDA) on Thursday authorized American pharmaceutical company Merck''s oral antiviral for the treatment of mild-to-moderate COVID-19, the second pill approved for treating COVID-19 following the one from Pfizer.

Regulators are signaling they prefer Pfizers pill, which theyve bought more of, but the US will have a lot more early on of Mercks pill, which is ''better'' than no treatment.

Dec. 23, 2021 -- The FDA has granted emergency exercise authorization to Mercks antiviral drug to manage with adults with soft to moderate COVID-19 who are at probability for extreme illness.Comparable to FDA authorization of one more antiviral pill regimen -- ritonavir plus nirmatrelvir, or Paxlovid -- granted to Pfizer on Wednesday, molnupiravir (label name

Indian giants Sun Pharmaceutical Industries, Optimus Pharma, and Dr Reddys Laboratories are exploring the possibility of manufacturing the pill, reports suggest.

The Indonesian rupiah hit its highest in nearly two months on Friday and was eyeing its best weekly gain since early May, boosted by improving market sentiment on hopes the Omicron coronavirus variant won''t damage the economy too much. Most other Asian emerging currencies clung to narrow ranges against the dollar, while equities were largely mixed in thin trading on Christmas Eve. Global markets, including major indexes on Wall Street, notched modest gains, with the S&P 500 closing at a record high overnight on signs that Omicron is less likely to lead to hospitalization. Vaccine makers AstraZeneca Plc and Novavax Inc said their shots protected against Omicron, and data indicated both Merck''s and Pfizer''s COVID-19 anti-viral pills are effective against the variant, providing another glimmer of hope to the markets. That put pressure on the dollar, which slipped marginally against a basket of currencies. The US dollar index was flat at 96.062, lingering near its one-week low. Analysts at Mizuho Bank termed it as a "Santa pause" which seemed to be more a consequence of heightened uncertainty amid conflicting economic risks and policy signals, than a "risk-on" holiday-cheer rally as more clarity is needed on the Omicron variant.

US approves Pfizer pill for COVID treatment Times of Oman

Bhattacharya: We Cannot Stop The Spread Of COVID, But We Can End The Pandemic Authored by Jayanta Bhattacharya via The Brownstone Institute, The arrival of the omicron variant has led some politicians and public health grandees to call for a return to business closures and circuit-breaker lockdowns. The variant has been found worldwide, including in the US and the UK. The variant has already surpassed delta dominant before omicron in the UK. Early reports from South Africa confirm that the variant is more transmissible but produces a milder disease, with a lower chance of hospitalization and death upon infection. My message is this: we cant stop the spread of COVID, but we can end the pandemic. In October 2020, I wrote the Great Barrington Declaration (GBD) along with Prof. Sunetra Gupta of Oxford University and Prof. Martin Kulldorff of Harvard University. The centerpiece of the declaration is a call for increased focused protection of the vulnerable older population, who are more than a thousand times more likely to die from COVID infection than the young.